Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2007-01-23
2007-01-23
Le, Long V. (Department: 1641)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C436S172000
Reexamination Certificate
active
10983780
ABSTRACT:
Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macula. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.
REFERENCES:
patent: 4778815 (1988-10-01), Cash
patent: 0 397 437 (1990-05-01), None
patent: WO 99/09981 (1999-03-01), None
Harding, J.J. Can cataract be prevented? (1999) Eye, 13:454-456.
Harding, J.J. Can drugs or micronutrients prevent cataract? (2001) Drugs & Aging 18:473-86.
Asbell et al. Age-related cataract. (2005) Lancet 365:599-609.
Pritchard et al. Making better drugs: Decision gates in non-clinical drug development. (2003) Nature Reviews Drug Discovery 2:542-553.
Lin et al. UV-B-induced secondary conformational changes in lens a-crystallin (1999) J. Photochem. Photobiol. B: Biology 49:29-34.
Aquilina, J.A., et al., “Elucidation of a Novel Polypeptide Cross-Link Involving 3-Hydroxykynurenine,”Biochemistry 38:11455-11464, American Chemical Society (Aug. 1999).
Augusteyn, R.C. and Koretz, J.F., “Hypothesis: A possible structure for α-crystallin,”FEBS Lett. 222:1-5, Elsevier Science Publishers B.V. (1987).
Barker, L.R., et al., “Common Problems Associated with Impaired Vision: Cataracts and Age-Related Macular Degeneration,” inPrinciples of Ambulatory Medicine, 4thEd., Barker, L.R., et al., eds., Williams and Wilkins Publishing, pp. 1416-1419 (1995).
Balaji, M., et al., “Copper levels in human mixed, nuclear brunescence, and posterior subcapsular cataract,”Br. J. Ophthalmol. 76:668-669, BMJ Publishing Group (1992).
Bando, M., et al., “Spectrophotometric Estimation of 3-OH L-Kynurenine O-β-Glucoside in the Human Lens,”J. Biochem. (Tokyo) 89:103-109, The Japanese Biochemical Society (1981).
Benavente, M.G. and Truscott, R.J.W., “Modification of Proteins by 3-Hydroxyanthranilic Acid: The Role of Lysine Residues,”Arch. Biochem. Biophys. 290:451-457, Academic Press, Inc. (1991).
Benedek, G.B., “Cataract as a Protein Condensation Disease: The Proctor Lecture,”Invest. Ophthalmol. Vis. Sci. 38:1911-1921, Association For Research In Vision And Ophthalmology (1997).
Beebe, D.C., “Nuclear cataracts and Nutrition: Hope for Intervention Early and Late in Life,”Invest. Ophthalmol. Vis. Sci. 39:1531-1534, Association For Research In Vision And Ophthalmology (1998).
Bhat, S.P., et al., “αB-crystallin exists as an independent protein in the heart and in the lens,”Eur. J. Biochem. 202:775-781, Springer International on behalf of the Federation of European Biochemical Societies (1991).
Bhuyan, K.C., et al., “Lipid Peroxidation in Cataract of the Human,”Life Sci. 38:1463-1471, Pergamon Press, Ltd. (1986).
Bindoli, A., et al., Biochemical and Toxicological Properties of the Oxidation Products of Catecholamines,Free Radic. Biol. Med. 13:391-405, Pergamon Press, Ltd. (1992).
Brown, N.A.P., et al., “Nutrition supplements and the eye,”Eye 12:127-133, Nature Publishing Group (1998).
Carrell, R.W., and Lomas, D.A., “Conformational disease,”The Lancet 350:134-138, Lancet Publishing Group (1997).
Carver, J.A., et al., “α-Crystallin: molecular chaperone and protein surfactant,”Biochem. Biophys. Acta 1204:195-206, Elsevier Science B.V. (1994).
Cekic, O., “Effect of cigarette smoking on copper, lead, and cadmium accumulation in human lens,”Br. J. Ophthalmol. 82:186-188, BMJ Publishing Group (1998).
Chen, Y.C., et al., “Molecular Evidence for the Involvement of Alpha Crystallin in the Colouration/Crosslinking of Crystallins in Age-related Nuclear Cataract,”Exp. Eye Res. 65:835-840, Academic Press, Ltd. (1997).
Chiarugi, A., et al., “The kynurenine metabolic pathway in the eye: studies on 3-hydroxykynurenine, a putative cataractogenic compound,”FEBS Lett. 453:197-200, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies (Jun. 1999).
Christen, S., et al., “Antioxidant activities of some tryptophan metabolites: Possible implication for inflammatory diseases,”Proc. Natl. Acad. Sci.USA 87:2506-2510, National Academy Press (1990).
Cook, C.S., and McGahan, M.C., “Copper concentration in cornea, iris, normal, and cataractous lenses and intraocular fluids of vertebrates,”Curr. Eye Res. 5:69-76, IRL Press, Ltd. (1986).
Dilley, K.J., and Pirie, A., “Changes to the Proteins of the Humans Lens Nucleus In Cataract,”Exp. Eye Res. 19:59-72, Academic Press (1974).
Dillon, J., “UV-B as a pro-aging and pro-cataract factor,”Documenta Ophtalmologica 88:339-344, Kluwer Academic Publishers (1995).
Dykens, J.A., et al., “Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate,”Biochem. Pharmacol. 36:211-217, Pergamon Journals,Ltd. (1987).
Fay et al., “Diseases of the Visual System,” inCecil's Textbook of Medicine, 21stEd., Goldman, L. and Bennett, J.C., eds., W.B. Saunders Company, pp. 2231-2232 (Oct. 1999).
Fecondo, J.V., and Augusteyn, R.C., “Superoxide Dismutase, Catalase and Glutathione Peroxidase in the Human Cataractous Lens,”Exp. Eye Res. 36:15-23, Academic Press Inc. (London), Ltd. (1983).
Flanagan, E.M., et al., “Neurotoxin Quinolinic Acid Is Selectively Elevated in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis,”J. Neurochem. 64:1192-1196, Raven Press, Ltd. (1995).
Goldstein, L.E., et al., “3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction,”Biochemistry 39:7266-7275, American Chemical Society (Jun. 2000).
Goshima, N., et al., “3-Hydroxykynurenine as O2 Scavenger in the Blowfly, Aldrichina Grahami,” Biochim.Biophys. Res. Comm. 139:666-672, Academic Press, Inc. (1986).
Groenen, P.J.T.A., et al., “Structure and modifications of the junior chaperone α-crystallin: From lens transparency to molecular pathology,”Eur. J. Biochem. 225:1-19, Springer International on behalf of the Federation of European Biochemical Societies (1994).
Gutteridge, J.M.C., “Bleomycin-detectable iron in knee-joint synovial fluid from arthritic patients and its relationship to the extracellular antioxidant activities of caeruloplasmin, transferrin and lactoferrin,”Biochem. J. 245:415-421, Portland Press On Behalf Of The Biochemical Society (1987).
Halliwell, B., and Gutteridge, J.M.C., “Oxygen toxicity, oxygen radicals, transition metals and disease,”Biochem J. 219:1-14, Royal Society of London (1984).
Halliwell, B., et al., “Metal ions and oxygen radical reactions in human inflammatory joint disease,”Phil. Trans. R. Soc. Lond. B: 311:659-671, Royal Society of London (1985).
Harding, J.J., “Conformational Changes in Human Lens Proteins in Cataract,”Biochem. J. 129:97-100, Portland Press On Behalf Of The Biochemical Society (1972).
Harding, J.J., “Cataract, Alzheimer's disease, and other conformational diseases,”Curr. Opin. Ophthalmol. 9:10-13, Rapid Science Publishers (1998).
Heyes, M.P., et al., “A mechanism of quinolinic acid formation by brain in inflammatory neurological disease,”Brain 116:1425-1450, Oxford University Press (1993).
Heyes, M.P., et al., “Poliovirus induces indoleamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain,”FASEB. J. 6:2977-2989, Federation of American Societies for Experimental Biology (1992).
Hiraku, Y., et al., “Metal-mediated oxidative damage to cellular and isolated DNA by c
Bush Ashley I.
Goldstein Lee E.
Foster Christine E.
Le Long V.
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
LandOfFree
Method for the identification of agents that inhibit or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the identification of agents that inhibit or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the identification of agents that inhibit or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3726287